- A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine StudyPriscilla Velentgas
Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA
Pharmacoepidemiol Drug Saf 17:1226-34. 2008..Implementation has addressed several issues relevant to creation of a large scale post-marketing drug safety surveillance system envisioned by the FDA's Sentinel Initiative...
- Risk of Guillain-Barré syndrome after meningococcal conjugate vaccinationPriscilla Velentgas
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
Pharmacoepidemiol Drug Saf 21:1350-8. 2012..We conducted a study to assess the risk of GBS after MCV4 vaccination using health plan administrative and claims data together with the review of primary medical records of potential cases...